Anticoagulation I Dr. Covert Flashcards
Dr. Covert EXAM IV (41 cards)
What factors contribute to Thrombosis?
Virchow’s Triad
-Endothelial Injury
-Abnormal Blood flow (long travel)
-Hypercoagulability (contraceptives, pregnancy, cancer therapy)
What tests assess clotting disorders?
intrinsic: PTT (play table tennis - inside)
normal: 25-35 sec
extrinsic pathway: PT (play tennis - outside)
normal: 12 sec
Reasons for prophylactic anticoagulation therapy
Some risk of clot
-Immobility in hospitalized patients (some) changes in blood
Reasons for full-dose anticoagulation
Big Risk of clot:
-Atrial fibrillation: change in blood flow, risk of stroke
-Mechanical heart valves: platelets will stick to it, endothelial injury, change in blood flow
-certain clotting disorder: hypercoagulable state
Presence of clot:
-Deep vein thrombosis
-Pulmonary embolism
What are the available Anticoagulants and MOA?
MOA: inhibit clotting or deplete clotting factors
Drugs:
-Warfarin blocks the reduction of Vitamin K -> which is needed for the carboxylation of factors
-DOACS ( direct oral anticoagulants): like apixaban
-heparin
-enoxaparin (LMWH)
Indication for Anticoagulants
-DVT
-PE
-Atrial fibrillation
-red clot: fibrin rich
What is the MOA of Antiplatelets?
MOA: inhibit platelet aggregation
drugs: Aspirin, P2Y12 inhibitors (clopidogrelel, prasugrel, ticagrelor)
white clot: platelet-rich
Indication of Antiplateteltes
-prevents platelet clots, makes the blood slippier
Indication:
-Ischemic stroke (preventing platelet clot -> stroke)
-coronary artery disease (CAD)
-peripheral artery disease
What are the injectable Anticoagulants?
-Unfractionated Heparin (UFH)
-Enoxaparin (LMWH)
MOA Heparin
-Potentiates antithrombin III (ATII) activity à Inactivates thrombin (Factor II) MOA and Factor Xa
Onset and duration:
IV: immediately (quick ON, quick OFF - useful right before surgery to turn OFF the anti coag state for surgery)
SQ: 20-30 min, OFF: 1-2h
How is heparin cleared?
Reticuloendothelial system (binds to endothelial cells)
NOT hepatically or renally cleared
Which tests are used to assess the activity of heparin?
Therapeutic drug monitoring
-heparin works on the intrinsic pathway
-aPTT, anti-Xa
What are the side effects of heparin and how can it be reversed?
ADE: Heparin-induced-thrombocytopenia (immune cells activate platelet-clotting), bleeding
-reverse agent: Protamine
Heparin-induced-thrombocytopenia
-platelets release PF4
-PF4 binds to the long tail of heparin -> the body reacts and release IgG -> IgG binds to PF4/heparin-complex -> the complex binds to endothelial cells
-> causing release of tissue factor -> tissue factor increases thrombin generation -> CLOTTING
all platelets are bound to the complex, patients have low platelets but still activate the clotting cascade
Platelet level in patients with HIT
low platelets
-high risk of clotting
-HIT is diagnosed based on the 4T score (likelihood of HIT, Lexicomp calculator)
-> if at risk -> DC heparin/enoxaparin and change to argatroban (direct thrombin inhibitor)
MOA Enoxaparin (LMWH)
Lovenox
Potentiates ATIII activity; Inactivates Factor Xa more than Factor II due to the short tail
Onset and duration Enoxaparin
Onset: SQ 1-3h
Duration: SQ 5-8h
How is Enoxaparin cleared?
Renally eliminated
Which heparin to use in dialysis patients or patients with poor kidney function?
Heparin
Enoxaparin is cleared renally
if the patient’s kidney is fine, can we still give heparin???
Which test to assess enoxaparin activity?
Therapeutic drug monitoring
Anti-Xa
ADR and reversing agent of enoxaparin
-less risk for heparin-induced-thrombocytopenia, bleeding
-reversing agent: Protamin
-> if patient is excessively bleeding, vomit blood, blood in stool
Prophylactic dosing Enoxaparin and heparin
Heparin: 5000 u SQ TID
Enoxaparin:
40 mg SQ daily
if BMI over 40: 40 mg SQ BID
if CrCl < 30 mL/min: 30 mg SQ daily
Full-dose Anticoagulation
-Heparin: 80 units/kg IV X 1, then 18 units/kg/h
-Enoxaparin: 1 mg/kg SQ BID (q12)
if CrCl < 30 mL/min : 1 mg/kg SQ daily (q24)
Monitor in Prophylactic Dosing
-usually not recommended
-consider when using enoxaparin at extremes of body weight or in patients with fluctuating renal function